Randomized, controlled trial of a 10-day course of amifloxacin versus trimethoprim-sulfamethoxazole in the treatment of acute, uncomplicated urinary tract infection. Amifloxacin Multi-Center Trial Group

Autor: Boyko, E J, Iravani, A, Silverman, M H, Schelling, D J, Wright, R A
Zdroj: Antimicrobial Agents and Chemotherapy; April 1990, Vol. 34 Issue: 4 p665-667, 3p
Abstrakt: We conducted a randomized controlled trial of orally administered amifloxacin versus trimethoprimsulfamethoxazole (TMP-SMX) as treatments of acute uncomplicated urinary tract infection in women. Amifloxacin at a dosage of 200 mg twice a day appeared as safe and effective as TMP-SMX, but amifloxacin at 400 mg twice a day tended to cause adverse events more frequently than did TMP-SMX.
Databáze: Supplemental Index